{'fraction_non_alphanumeric': 0.033045977011494254, 'fraction_numerical': 0.0028735632183908046, 'mean_word_length': 5.97, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Secondary Prevention of Hyperkalemia With Sodium Polystyrene Sulfonate in Cardiac and Kidney Patients on Renin‐Angiotensin‐Aldosterone System Inhibition Therapy

Hyperkalemia, induced by renin‐angiotensin‐aldosterone system inhibition (RAAS‐I) in patients with chronic kidney disease (CKD), or cardiac disease often leads to withdrawal of RAAS‐I therapy. Sodium polystyrene sulfonate (SPS) is a potassium‐binding resin used for the treatment of hyperkalemia. Recently, concerns about the safety and efficacy of SPS were raised. We report here a follow‐up of 14 patients with CKD and heart disease on RAAS‐I treatment who were treated with low‐dose daily SPS to prevent recurrence of hyperkalemia.